research into effective treatment for the bone cancer
myeloma is to receive £1.3m from the Medical Research
Council. Over the next five years, 1,600 patients suffering
from multiple myeloma will participate in a national clinical
trial, looking at different drugs used to treat the condition.
trial will also link with Leukaemia Research Fund-supported
research at the University looking at the genetic abnormalities
of the disease, with a view to defining high and low risk
groups of patients.
is a form of cancer which affects antibody-producing plasma
cells in the bone marrow, and as most patients have evidence
of disease at a number of sites in the body, the condition
is known as multiple myeloma. About 200 new cases are
diagnosed each year in the UK.
new trial will address several questions relating to treatment,
and is also linked with important scientific studies to
improve understanding of the disease. The trial will compare
the effectiveness of various drug sequences to assess
their impact on response rates, duration of remission,
survival and quality of life.
some patients, the effectiveness of a treatment called
a mini-allogeneic transplant will be assessed.
This treatment involves relatively low levels of chemotherapy
followed by a transplant of stem cells from a tissue-compatible
funding has been awarded to principal investigators Dr
Tony Child and Professor Gareth Morgan from haematology
and oncology and to Julia Brown and Sue Bell of the NYCTRU,
who will co-ordinate the trial.